Craig Thompson has become president and CEO of Neurana Pharmaceuticals Inc. Prior to Neurana, Thompson served as president and CEO of Anthera Pharmaceuticals Inc. Before Anthera, he was chief operating officer of Tetraphase Pharmaceuticals Inc. Prior to Tetraphase, he was chief commercial officer for Trius Therapeutics Inc. He holds a bachelor of commerce degree from McMaster University and an M.B.A. from the University of Notre Dame. Neurana Pharmaceuticals is a private company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the neck and back and spasticity.
Joan Janulis is now senior VP of global regulatory affairs at Slayback Pharma LLC. Janulis is a highly accomplished regulatory affairs leader with extensive knowledge of the U.S. FDA regulations and best practices and a stellar track record on both the generic pharma as well as the 505b2 side. She served 11 years with Lachman Consultants, a premier pharmaceutical consulting company, where she was the VP and head of the Regulatory Practice and also served on Lachman’s board of directors. Janulis has held various executive positions at Vensun, Faulding/Purepac Pharmaceutical (now Actavis), Ivax Pharmaceuticals (now Teva), and Able Laboratories. Slayback is a N.J.- based pharmaceutical company focused on the development of complex generic and specialty pharmaceutical products.